Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation

Zhanwang Xiang, Mingjun Bai, Guohong Li, Bihui Zou, Zhihui Zhong, Fei Gao, Chun Wu, Mingsheng Huang, Fu-Jun Zhang

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the safety and efficacy of 125I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation. Materials and methods: We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3–6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided 125I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B). Results: The median survival time was 19 months (range of 3–36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred. Conclusion: CT-guided 125I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.

Original languageEnglish (US)
Pages (from-to)1907-1916
Number of pages10
JournalJournal of cancer research and clinical oncology
Volume145
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Brachytherapy
Hepatocellular Carcinoma
Disease-Free Survival
Safety
Recurrence
Lung
Survival
alpha-Fetoproteins
Tomography
Radiosurgery
Neoplasms
Hemorrhage
Therapeutics

Keywords

  • Bilateral lung recurrences
  • Efficacy
  • Hepatocellular carcinoma
  • I brachytherapy
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation. / Xiang, Zhanwang; Bai, Mingjun; Li, Guohong; Zou, Bihui; Zhong, Zhihui; Gao, Fei; Wu, Chun; Huang, Mingsheng; Zhang, Fu-Jun.

In: Journal of cancer research and clinical oncology, Vol. 145, No. 7, 01.07.2019, p. 1907-1916.

Research output: Contribution to journalArticle

Xiang, Zhanwang ; Bai, Mingjun ; Li, Guohong ; Zou, Bihui ; Zhong, Zhihui ; Gao, Fei ; Wu, Chun ; Huang, Mingsheng ; Zhang, Fu-Jun. / Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation. In: Journal of cancer research and clinical oncology. 2019 ; Vol. 145, No. 7. pp. 1907-1916.
@article{c63a78a4c9fa4b56a167449fea4700fc,
title = "Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation",
abstract = "Purpose: To evaluate the safety and efficacy of 125I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation. Materials and methods: We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3–6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided 125I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B). Results: The median survival time was 19 months (range of 3–36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8{\%}, 65.9{\%}, 59.1{\%}, 45.0{\%}, 38.6{\%}, 22.7{\%}, 11.4{\%}, respectively, and 64.7{\%}, 47.1{\%}, 33.3{\%}, 25.4{\%}, 15.7{\%}, 11.7{\%}, 7.8{\%}, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred. Conclusion: CT-guided 125I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.",
keywords = "Bilateral lung recurrences, Efficacy, Hepatocellular carcinoma, I brachytherapy, Safety",
author = "Zhanwang Xiang and Mingjun Bai and Guohong Li and Bihui Zou and Zhihui Zhong and Fei Gao and Chun Wu and Mingsheng Huang and Fu-Jun Zhang",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s00432-019-02943-x",
language = "English (US)",
volume = "145",
pages = "1907--1916",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation

AU - Xiang, Zhanwang

AU - Bai, Mingjun

AU - Li, Guohong

AU - Zou, Bihui

AU - Zhong, Zhihui

AU - Gao, Fei

AU - Wu, Chun

AU - Huang, Mingsheng

AU - Zhang, Fu-Jun

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose: To evaluate the safety and efficacy of 125I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation. Materials and methods: We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3–6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided 125I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B). Results: The median survival time was 19 months (range of 3–36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred. Conclusion: CT-guided 125I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.

AB - Purpose: To evaluate the safety and efficacy of 125I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation. Materials and methods: We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3–6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided 125I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B). Results: The median survival time was 19 months (range of 3–36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred. Conclusion: CT-guided 125I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.

KW - Bilateral lung recurrences

KW - Efficacy

KW - Hepatocellular carcinoma

KW - I brachytherapy

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85066818930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066818930&partnerID=8YFLogxK

U2 - 10.1007/s00432-019-02943-x

DO - 10.1007/s00432-019-02943-x

M3 - Article

C2 - 31161374

AN - SCOPUS:85066818930

VL - 145

SP - 1907

EP - 1916

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 7

ER -